Mark Minden

Title: Mark Minden: Innovator in Acute Myeloid Leukemia Prognosis

Introduction

Mark Minden is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of medical research, particularly in the area of acute myeloid leukemia (AML). His innovative approach to classifying high-risk AML patients has the potential to improve patient outcomes and treatment strategies.

Latest Patents

Mark Minden holds a patent for a method that identifies high-risk AML patients. This patent describes a method of prognosing or classifying a subject with acute myeloid leukemia by determining the expression level of at least three genes in a test sample. The genes involved include DNMT3B, ZBTB46, NYNRIN, and several others. The method compares the expression levels in the test sample with reference levels from control samples, allowing for the classification of patients into low or high-risk groups based on their survival prospects.

Career Highlights

Mark Minden is affiliated with the University Health Network, where he conducts his research. His work has garnered attention for its potential to enhance the understanding and treatment of AML. With a focus on gene expression and patient classification, Minden's research is paving the way for more personalized medical approaches.

Collaborations

Mark collaborates with esteemed colleagues such as John Dick and Jean Wang. Their combined expertise contributes to the advancement of research in leukemia and other hematological conditions.

Conclusion

Mark Minden's innovative work in the field of acute myeloid leukemia prognosis exemplifies the impact of research on patient care. His patent and collaborations highlight the importance of continued innovation in medical science.